Healthcare

Asgard Therapeutics will develop cancer therapies which use reprogrammed human skin cells to improve the immune system’s capacity to identify cancerous particles.

Foresite Capital and F-Prime Capital joined earlier series B investors including Oxford Science Innovations to take Oxford drug discovery spinout Genomics’ total funding to $58.2m.

Oxford drug delivery spinout Evox Therapeutics collected funding from Bill and Melinda Gates Foundation in its bid to engineer exosome delivery vessels for a range of drugs.

Cambridge neural interface spinout Bios will use some of the seed capital to develop an interface between prosthetic objects and the human nervous system.

Vascudyne will develop vascular medical devices offering enhanced performance on the back of a stem cell-grown tissue with similar biological and mechanical qualities to the native equivalent.

The KCL immuno-oncology spinout’s second series A close included investment from UCL Technology Fund, Alsa Holding and Epidarex Capital.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.

Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.

Versant's unusual build-to-buy model has resulted in Roche acquiring a target for MS based on UCSF research and the venture firm launching a new spinout, Pipeline Therapeutics.